UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 87

Sortiert nach

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

The New England journal of medicine, 2017-06, Vol.376 (25), p.2427-2436

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

Expert review of vaccines, 2023-12, Vol.22 (1), p.501-517

2023

Link zum Volltext

Verfügbarkeit prüfen

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial

The Journal of infectious diseases, 2010-02, Vol.201 (4), p.590-599

2010

Link zum Volltext

Verfügbarkeit prüfen

Recombinant hemagglutinin influenza vaccine provides broader spectrum protection

Expert review of vaccines, 2016-08, Vol.15 (8), p.957-966

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE + GLA) adjuvant

Vaccine, 2013-11, Vol.31 (48), p.5760-5765

2013

Link zum Volltext

Verfügbarkeit prüfen

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial

Vaccine, 2023-05, Vol.41 (22), p.3461-3466

2023

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults

Vaccine, 2023-09, Vol.41 (41), p.5965-5973

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age

The Journal of infectious diseases, 2017-12, Vol.216 (10), p.1219-1226

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial

Pediatrics (Evanston), 2018-05, Vol.141 (5)

2018

Link zum Volltext

Verfügbarkeit prüfen

Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines

The Journal of infection, 2024-03, Vol.88 (3), p.106119-106119

2024

Link zum Volltext

Verfügbarkeit prüfen

Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial

Vaccine, 2017-02, Vol.35 (6), p.923-928

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age

Vaccine, 2015-11, Vol.33 (48), p.6622-6628

2015

Link zum Volltext

Verfügbarkeit prüfen

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

AIDS (London), 2007-06, Vol.21 (10), p.1293-1299

2007

Link zum Volltext

Verfügbarkeit prüfen

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5

Virology (New York, N.Y.), 2010-04, Vol.400 (1), p.145-155

2010

Link zum Volltext

Verfügbarkeit prüfen

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials

The Journal of infection, 2012-10, Vol.65 (4), p.326-335

2012

Link zum Volltext

Verfügbarkeit prüfen

Determination of Dosing Guidelines for Stavudine (2′,3′-Didehydro-3′-Deoxythymidine) in Children with Human Immunodeficiency Virus Infection

Antimicrobial Agents and Chemotherapy, 2001-03, Vol.45 (3), p.758-763

2001

Link zum Volltext

Verfügbarkeit prüfen

A Controlled Trial of Acyclovir for Chickenpox in Normal Children

The New England journal of medicine, 1991-11, Vol.325 (22), p.1539-1544

1991

Link zum Volltext

Verfügbarkeit prüfen

Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine

Clinical infectious diseases, 2024-02

2024

Link zum Volltext

Verfügbarkeit prüfen

Randomized comparison of the safety of Flublok registered versus licensed inactivated influenza vaccine in healthy, medically stable adults greater than or equal to 50 years of age

Vaccine, 2015-11, Vol.33 (48), p.6622-6628

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection

Pediatrics (Evanston), 1995-08, Vol.96 (2 Pt 1), p.247

1995

Link zum Volltext

Verfügbarkeit prüfen

The spectrum of fusobacterial infections in children

The Pediatric infectious disease journal, 1990-07, Vol.9 (7), p.505-508

1990

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 87

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(86)
Buchkapitel
(1)

Sprache

Englisch
(87)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(62)
Humans
(60)
Male
(37)
Female
(36)
Biological And Medical Sciences
(28)
Immunology
(27)
Medical Sciences
(24)
Pediatrics
(24)
Adult
(22)
Child
(20)
Infectious Diseases
(20)
Middle Aged
(18)
Adolescent
(17)
Child, Preschool
(17)
Infant
(16)
Aids/hiv
(15)
Microbiology
(15)
Pharmacology. Drug Treatments
(14)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial

Recombinant hemagglutinin influenza vaccine provides broader spectrum protection

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE + GLA) adjuvant

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial

Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults

Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial

Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials

Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial

Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials

Determination of Dosing Guidelines for Stavudine (2′,3′-Didehydro-3′-Deoxythymidine) in Children with Human Immunodeficiency Virus Infection

A Controlled Trial of Acyclovir for Chickenpox in Normal Children

Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine

Randomized comparison of the safety of Flublok registered versus licensed inactivated influenza vaccine in healthy, medically stable adults greater than or equal to 50 years of age

A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection

The spectrum of fusobacterial infections in children

Suchergebnisse filtern